METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets genetic weakness in advanced prostate cancer
Disease control OngoingThis phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to slow spread of prostate cancer
Disease control OngoingThis Phase 3 trial tests whether adding the experimental drug saruparib to standard hormone therapy can slow cancer growth in men with metastatic prostate cancer that still responds to hormone treatment. About 1,889 men will receive either saruparib or a placebo, plus a hormone d…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a smarter hormone schedule keep prostate cancer in check longer?
Disease control OngoingThis study tests a new approach for men with stage IV prostate cancer that still responds to hormone therapy. Instead of continuous hormone treatment, doctors adjust the timing based on PSA levels and add chemotherapy. The goal is to see if this strategy can keep the cancer sensi…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC